Arab Journal of Gastroenterology
Volume 10, Issue 1 , Pages 1-3, March 2009

Antischistosomal therapy: Current status and recent developments

Tropical Medicine Department, Faculty of Medicine, Cairo University, Cairo, Egypt

Abstract 

Schistosomiasis remains one of the most prevalent parasitic infections in the world. Currently, Praziquantel (PZQ) is the drug being used to treat human schistosomiasis on a large scale. Millions of people are treated annually with praziquantel, and drug-resistant parasites thus are likely to evolve. This review focuses on current knowledge about the mechanisms of action of PZQ, possibility of PZQ resistance, potentially alternative drugs, and prospects for development of new schistosomicides .Vaccines production strategies represent an essential component for the future control of schistosomiasis as an adjunct to chemotherapy.

Keywords: Schistosomiasis, Parasites, Antischistosomal drugs, Praziquantil

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1687-1979(09)00008-2

doi:10.1016/j.ajg.2009.03.002

Arab Journal of Gastroenterology
Volume 10, Issue 1 , Pages 1-3, March 2009

Article Tools